<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30214581</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Print">1792-1074</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>16</Volume>                    <Issue>4</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Oncology letters</Title>                <ISOAbbreviation>Oncol Lett</ISOAbbreviation>            </Journal>            <ArticleTitle>Aberrant promoter methylation of PCDH10 as a potential diagnostic and prognostic biomarker for patients with breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>4462-4470</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3892/ol.2018.9214</ELocationID>            <Abstract>                <AbstractText>Protocadherin-10 (PCDH10) is a tumor suppressor gene. Its expression level is downregulated by promoter methylation in certain types of human tumors. The aim of the present study was to examine the expression level and promoter methylation status of PCDH10 in breast cancer cells and to evaluate the association of PCDH10 methylation and tumor progression and prognosis. MethyLight was used to detect the methylation status of PCDH10 in breast cancer tissues and healthy breast tissues. Reverse transcription-quantitative polymerase chain reaction was used to assess the mRNA expression level of PCDH10, as well as to evaluate the association between PCDH10 methylation and clinicopathological features, along with patients' overall survival (OS). PCDH10 5'-C-phosphate-G-3' (CpG) methylated sites were identified in tumor tissues and matched healthy tissues (n=392). Tumor tissues and matched healthy tissues exhibited identifiable PCR results, with PCDH10 gene promoter methylation identified in ductal carcinoma <i>in situ</i> (66%), invasive ductal carcinoma (82%), invasive ductal carcinoma with lymph node metastasis (85.32%) and hereditary breast cancer tissues (72.37%). PCDH10 mRNA expression was significantly decreased in breast cancer tissues compared with healthy breast tissues (P=0.032). PCDH10 methylation was associated with tumor size (P=0.004), but not associated with other clinical factors. Survival analysis revealed that the patients exhibiting methylated-PCDH10 had significantly poorer OS times than patients exhibiting unmethylated-PCDH10 (P&lt;0.0001). Receiver operating characteristic analysis indicated a sensitivity of 75%, a specificity of 62.5%, and an area under the curve of 0.682 for PCDH10. Additionally, the results of the present study indicated that PCDH10 methylation status may be a useful diagnostic and prognostic evaluation biomarker for breast cancer. The results suggested that PCDH10 methylation is a common occurrence in primary breast cancer and is associated with poor survival rates among patients with breast cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Wentao</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>Jin</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shi</LastName>                    <ForeName>Guangyue</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yue</LastName>                    <ForeName>Xiaolong</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Dan</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Qingyuan</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>25</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Greece</Country>            <MedlineTA>Oncol Lett</MedlineTA>            <NlmUniqueID>101531236</NlmUniqueID>            <ISSNLinking>1792-1074</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2003 Apr 18;300(5618):455</RefSource>                <PMID Version="1">12702868</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Epigenetics. 2018 Jan 25;10:12</RefSource>                <PMID Version="1">29416570</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pediatr Blood Cancer. 2017 Mar;64(3):</RefSource>                <PMID Version="1">27643535</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 1999 May;17(5):1474-81</RefSource>                <PMID Version="1">10334533</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2004 Jun 1;64(11):3807-13</RefSource>                <PMID Version="1">15172987</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Prev Res (Phila). 2010 Jan;3(1):16-24</RefSource>                <PMID Version="1">20051369</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2014 Jun;15(7):e279-89</RefSource>                <PMID Version="1">24872111</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PeerJ. 2016 Jun 09;4:e2112</RefSource>                <PMID Version="1">27330867</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2010 Apr 8;29(14):2104-17</RefSource>                <PMID Version="1">20154727</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Mol Diagn. 2006 May;8(2):209-17</RefSource>                <PMID Version="1">16645207</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharmacogenomics. 2008 Dec;9(12):1879-902</RefSource>                <PMID Version="1">19072646</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2009 Nov 1;125(9):2214-8</RefSource>                <PMID Version="1">19621443</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Metab. 2018 Feb 27;:null</RefSource>                <PMID Version="1">29525406</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Epigenetics. 2012 Jul;7(7):701-9</RefSource>                <PMID Version="1">22647880</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2010;12(1):R3</RefSource>                <PMID Version="1">20056007</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell Cycle. 2015;14(6):857-66</RefSource>                <PMID Version="1">25590240</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Genet. 2009 Apr;10(4):241-51</RefSource>                <PMID Version="1">19293820</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Methods. 2001 Dec;25(4):402-8</RefSource>                <PMID Version="1">11846609</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast J. 2008 Jan-Feb;14(1):3-13</RefSource>                <PMID Version="1">18086272</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Cancer Res. 2014 Nov 19;4(6):710-24</RefSource>                <PMID Version="1">25520862</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2012 Jan;131(1):197-205</RefSource>                <PMID Version="1">21837480</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genomics. 2001 Aug;76(1-3):66-72</RefSource>                <PMID Version="1">11549318</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Biomark. 2015;15(5):567-73</RefSource>                <PMID Version="1">26406945</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Exp Mol Pathol. 2016 Apr;100(2):344-52</RefSource>                <PMID Version="1">26970279</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2006 Feb 16;25(7):1070-80</RefSource>                <PMID Version="1">16247458</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2009 Jun 15;69(12):5251-8</RefSource>                <PMID Version="1">19509227</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2005 Sep 1;116(3):407-14</RefSource>                <PMID Version="1">15818620</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Biomark. 2012-2013;12(1):11-9</RefSource>                <PMID Version="1">23321465</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2006 Feb;6(2):107-16</RefSource>                <PMID Version="1">16491070</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Prostate. 2012 Aug 1;72(11):1248-61</RefSource>                <PMID Version="1">22161815</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2008 Mar 13;358(11):1148-59</RefSource>                <PMID Version="1">18337604</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2008 Nov 13;359(20):2143-53</RefSource>                <PMID Version="1">19005198</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer. 2016 Jan 29;7(4):446-52</RefSource>                <PMID Version="1">26918058</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62</RefSource>                <PMID Version="1">24114568</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Nov 15;7(46):75307-75318</RefSource>                <PMID Version="1">27659532</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2008 Jan 17;358(3):213-6</RefSource>                <PMID Version="1">18199859</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Rev Mol Diagn. 2013 Jun;13(5):445-55</RefSource>                <PMID Version="1">23782252</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nucleic Acids Res. 2000 Apr 15;28(8):E32</RefSource>                <PMID Version="1">10734209</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Fertil Steril. 2015 Jul;104(1):145-53.e6</RefSource>                <PMID Version="1">25956362</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Genet. 2007 Apr;8(4):286-98</RefSource>                <PMID Version="1">17339880</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2002 Aug 12;21(35):5380-7</RefSource>                <PMID Version="1">12154400</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Genet. 1994 Jul;7(3):376-82</RefSource>                <PMID Version="1">7920655</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Genomics. 2015 Oct 28;16:873</RefSource>                <PMID Version="1">26510534</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2009 Mar 10;27(8):1168-76</RefSource>                <PMID Version="1">19204205</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer. 2003;10(3):234-40</RefSource>                <PMID Version="1">12955036</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer Res Clin Oncol. 2013 Mar;139(3):485-90</RefSource>                <PMID Version="1">23180019</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogenesis. 2015 Jun 15;4:e157</RefSource>                <PMID Version="1">26075748</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 2016 Jul;36(1):383-9</RefSource>                <PMID Version="1">27176920</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Mol Med. 2012 Apr;29(4):704-10</RefSource>                <PMID Version="1">22245948</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2015 Apr 07;10(4):e0123523</RefSource>                <PMID Version="1">25849101</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Genet. 2006 Jan;7(1):21-33</RefSource>                <PMID Version="1">16369569</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2006 May 1;66(9):4617-26</RefSource>                <PMID Version="1">16651412</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cell. 2013 Sep 26;155(1):39-55</RefSource>                <PMID Version="1">24074860</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Methods Enzymol. 2013;529:35-45</RefSource>                <PMID Version="1">24011035</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Plast Reconstr Aesthet Surg. 2009 Feb;62(2):181-9</RefSource>                <PMID Version="1">19027378</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2007 May 15;67(10):4545-9</RefSource>                <PMID Version="1">17510378</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 2007 Jun;17(6):1279-90</RefSource>                <PMID Version="1">17487380</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Gastroenterology. 2009 Feb;136(2):640-51.e1</RefSource>                <PMID Version="1">19084528</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genome Res. 2012 Feb;22(2):407-19</RefSource>                <PMID Version="1">21613409</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 1997 May 29;71(5):800-9</RefSource>                <PMID Version="1">9180149</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 2012 Sep 7;337(6099):1190-5</RefSource>                <PMID Version="1">22955828</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Mol Genet. 2001 Dec 15;10(26):3001-7</RefSource>                <PMID Version="1">11751682</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2018 Aug;37(35):4769-4780</RefSource>                <PMID Version="1">29780167</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Tumour Biol. 2016 Oct;37(10):12969-12981</RefSource>                <PMID Version="1">27449047</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Carcinogenesis. 2010 Jun;31(6):1027-36</RefSource>                <PMID Version="1">20200074</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Sci Monit. 2016 Feb 16;22:516-21</RefSource>                <PMID Version="1">26881880</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Viral Hepat. 2015 Feb;22(2):201-11</RefSource>                <PMID Version="1">24910204</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Hum Pathol. 1996 Oct;27(10):1050-5</RefSource>                <PMID Version="1">8892589</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2004 Jun 10;23(27):4793-806</RefSource>                <PMID Version="1">15122337</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2009 Nov;100(11):2175-80</RefSource>                <PMID Version="1">19709077</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">diagnosis</Keyword>            <Keyword MajorTopicYN="N">methylation</Keyword>            <Keyword MajorTopicYN="N">overall survival</Keyword>            <Keyword MajorTopicYN="N">prognosis</Keyword>            <Keyword MajorTopicYN="N">protocadherin-10</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>07</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30214581</ArticleId>            <ArticleId IdType="doi">10.3892/ol.2018.9214</ArticleId>            <ArticleId IdType="pii">OL-0-0-9214</ArticleId>            <ArticleId IdType="pmc">PMC6126325</ArticleId>        </ArticleIdList>        <?pmcsd?>    </PubmedData></PubmedArticle></PubmedArticleSet>